Monthly Prescribing Reference

GPRC5D-Targeting Bispecific Antibody Gets Orphan Drug Status for Multiple Myeloma

LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.